Purpose/Objectives: To review the prevalence, consequences, patho-physiology, diagnosis, and treatment of cancer treatment-induced bone loss (CTIBL) in patients with breast or prostate cancer.
Data Sources: Published articles, abstracts, book chapters, electronic resources, and manufacturer information.
Data Synthesis: CTIBL is a long-term complication associated with cancer therapies that cause hypogonadism in patients with breast or prostate cancer. Early diagnosis and treatment of CTIBL is essential to prevent bone fractures. CTIBL treatment includes modification of lifestyles that increase the risk of developing bone loss and fractures and includes the use of bone loss therapies (e.g., bisphosphonates, selective estrogen receptor modifiers, calcitonin).
Conclusions: CTIBL is becoming more common as patients with breast or prostate cancer survive longer. Identifying and treating CTIBL early are important because once bone is lost, damaged bone becomes more difficult to repair; early diagnosis and treatment also may prevent fractures.
Implications for Nursing: Nurses must be knowledgeable about CTIBL to identify high-risk patients and educate patients and their families about CTIBL, bone loss therapies, and lifestyle modifications.
Basaria, S., Lieb, J., II, Tang, A.M., DeWeese, T., Carducci, M., Eisenberger, M., et al. (2002). Long-term effects of androgen deprivation therapy in prostate cancer patients. Clinical Endocrinology, 56, 779-786.
Baum, M., Buzdar, A.U., Cuzick, J., Forbes, J., Houghton, J.H., Klijn, J.G., et al. (2002). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet, 359, 2131-2139.
Begerow, B., Pfeifer, M., Pospeschill, M., Scholz, M., Schlotthauer, T., Lazarescu, A., et al. (1999). Time since vertebral fracture: An important variable concerning quality of life in patients with postmenopausal osteoporosis. Osteoporosis International, 10, 26-33.
Berruti, A., Dogliotti, L., Terrone, C., Cerutti, S., Isaia, G., Tarabuzzi, R., et al. (2002). Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. Journal of Urology, 167, 2361-2367.
Berruti, A., Tucci, M., Terrone, C., Gorzegno, G., Scarpa, R.M., Angeli, A., et al. (2002). Background to and management of treatment-related bone loss in prostate cancer. Drugs and Aging, 19, 899-910.
Bines, J., Oleske, D.M., & Cobleigh, M.A. (1996). Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. Journal of Clinical Oncology, 14, 1718-1729.
Brown, J.P., & Josse, R.G. (2002). 2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada. Canadian Medical Association Journal, 167(10, Suppl.), S1-S34.
Bruning, P.F., Pit, M.J., de Jong-Bakker, M., van den Ende, A., Hart, A., & van Enk, A. (1990). Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. British Journal of Cancer, 61, 308-310.
Center, J.R., Nguyen, T.V., Schneider, D., Sambrook, P.N., & Eisman, J.A. (1999). Mortality after all major types of osteoporotic fracture in men and women: An observational study. Lancet, 353, 878-882.
Chen, Z., Maricic, M., Nguyen, P., Ahmann, F.R., Bruhn, R., & Dalkin, B.L. (2002). Low bone density and high percentage of body fat among men who were treated with androgen deprivation therapy for prostate carcinoma. Cancer, 95, 2136-2144.
ClinicalTrials.gov. (2004a). Calcium with or without estrogen and/or risedronate in preventing osteoporosis in patients with prostate cancer. Retrieved February 23, 2004, from http://clinicaltrials.gov/ct/show/NCT00043069?order=1
ClinicalTrials.gov. (2004b). Risedronate in preventing bone loss in premenopausal women receiving chemotherapy for primary breast cancer. Retrieved February 23, 2004, from http://clinicaltrials.gov/ct/show/NCT00054418?order=2
ClinicalTrials.gov. (2004c). Tamoxifen to prevent bone loss and heart disease in premenopausal women receiving chemotherapy for stage I or stage II breast cancer. Retrieved February 23, 2004, from http://clinicaltrials.gov/ct/show/NCT00005605?order=1
ClinicalTrials.gov. (2004d). Zoledronate and estradiol in preventing bone loss in patients with prostate cancer. Retrieved February 23, 2004, from http://clinicaltrials.gov/ct/show/NCT00049491?order=1
ClinicalTrials.gov. (2004e). Zoledronate, calcium, and vitamin D in preventing bone loss in women receiving adjuvant chemotherapy for breast cancer. Retrieved February 23, 2004, from http://clinicaltrials.gov/ct/show/NCT00022087?order=1
ClinicalTrials.gov. (2004f). Zoledronate in preventing bone loss in premenopausal women receiving chemotherapy after surgery for early stage breast cancer. Retrieved February 23, 2004, from http://clinicaltrials.gov/ct/show/NCT00049452?order=9
Coombes, R.C., Hall, E., Gibson, L.J., Paridaens, R., Jassem, J., Delozier, T., et al. (2004). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. New England Journal of Medicine, 350, 1081-1092.
Cooper, C. (1997). The crippling consequences of fractures and their impact on quality of life. American Journal of Medicine, 103(2A), 12S-17S.
Cummings, S.R., Bates, D., & Black, D.M. (2002). Clinical use of bone densitometry: Scientific review. JAMA, 288, 1889-1897.
Cummings, S.R., & Melton, L.J., III. (2002). Epidemiology and outcomes of osteoporotic fractures. Lancet, 359, 1761-1767.
Daniell, H.W. (1997). Osteoporosis after orchiectomy for prostate cancer. Journal of Urology, 157, 439-444.
Daniell, H.W., Dunn, S.R., Ferguson, D.W., Lomas, G., Niazi, Z., & Stratte, P.T. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. Journal of Urology, 163, 181-186.
Dawson-Hughes, B., Harris, S.S., Krall, E.A., & Dallal, G.E. (1997). Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. New England Journal of Medicine, 337, 670-676.
Delmas, P.D. (2002). Treatment of postmenopausal osteoporosis. Lancet, 359, 2018-2026.
Delmas, P.D., Balena, R., Confravreux, E., Hardouin, C., Hardy, P., & Bremond, A. (1997). Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: A double-blind, placebo-controlled study. Journal of Clinical Oncology, 15, 955-962.
Delmas, P.D., Eastell, R., Garnero, P., Seibel, M.J., & Stepan, J. (2000). The use of biochemical markers for bone turnover in osteoporosis. Osteoporosis International, 11(Suppl. 6), S2-S17.
Diamond, T., Campbell, J., Bryant, C., & Lynch, W. (1998). The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma. Longitudinal evaluation and response to intermittent cyclic etidronate therapy. Cancer, 83, 1561-1566.
Diamond, T.H., Higano, C.S., Smith, M.R., Guise, T.A., & Singer, F.R. (2004). Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: Recommendations for diagnosis and therapies. Cancer, 100, 892-899.
Diamond, T.H., Winters, J., Smith, A., De Souza, P., Kersley, J.H., Lynch, W.J, et al. (2001). The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combine androgen blockade: A double blind, randomized, placebo-controlled crossover study. Cancer, 92, 1444-1450.
Eastell, R., Hannon, R.A., Cuzick, J., Clack, G., & Adams, J.E. (2002). Effect of anastrozole on bone density and bone turnover: Results of 'Arimidex' (anastrozole), tamoxifen, alone or in combination (ATAC) study. Abstract 1170 presented at the 24th annual meeting of the American Society of Bone and Mineral Research, San Antonio, TX.
Eriksson, S., Eriksson, A., Stege, R., & Carlstrom, K. (1995). Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens. Calcified Tissue International, 57, 97-99.
Finkelstein, J.S. (2000). Osteoporosis. In L. Goldman & J.C. Bennett (Eds.), Cecil textbook of medicine (21st ed., pp. 1366-1373). Philadelphia: Saunders.
Follin, S.L. (2003). Update in osteoporosis. In B.A. Mueller, K.E. Bertch, T.S. Dunsworth, S.C. Fagan, M.S. Hayney, M.B. O'Connell, et al. (Eds.), Pharmacotherapy self-assessment program: Book 11 women's health, men's health (4th ed., pp. 329-366). Kansas City, MO: American College of Clinical Pharmacy.
Gholz, R.C., Conde, F., & Rutledge, D.N. (2002). Osteoporosis in men treated with androgen suppression therapy for prostate cancer. Clinical Journal of Oncology Nursing, 6, 88-93.
Gnant, M., Hausmaninger, H., Samonigg, H., Mlineritsch, B., Taucher, S., Luschin-Ebengreuth, G., et al. (2002). Changes in bone mineral density caused by anastrozole or tamoxifen in combination with goserelin (± zoledronate) as adjuvant treatment for hormone receptor-positive premenopausal breast cancer: Results of a randomized multicenter trial. Breast Cancer Research and Treatment, 76(Suppl.), 531.
Goss, P.E. (2004). NCIC CTG MA.17: Final analysis of updated data. A placebo-controlled trial of letrozole following tamoxifen as adjuvant therapy in postmenopausal women with early stage breast cancer. Presentation at the 40th annual meeting of the American Society of Clinical Oncology, New Orleans, LA.
Goss, P.E., Ingle, J.N., Martino, S., Robert, N.J., Muss, H.B., Piccart, M.J., et al. (2003). A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. New England Journal of Medicine, 349, 1793-1802.
Graham, D.Y., & Malaty, H.M. (2001). Alendronate and naproxen are synergistic for development of gastric ulcers. Archives of Internal Medicine, 161, 107-110.
Hatano, T., Oishi, Y., Furuta, A., Iwamuro, S., & Tashiro, K. (2000). Incidence of bone fracture in patients receiving luteinizing hormone-releasing agonists for prostate cancer. British Journal of Urology International, 86, 449-452.
Higano, C.S. (2003). Bone loss and the evolving role of bisphosphonate therapy in prostate cancer. Urologic Oncology, 21, 392-398.
Higano, C.S. (2004). Understanding treatments for bone loss and bone metastases in patients with prostate cancer: A practical review and guide for the clinician. Urologic Clinics of North America, 31, 331-352.
Higano, C.S., Jiang, P.Y.Z., Miller, M., Pitzel, M., & Jensen, M. (2003). Prospective evaluation of bone mineral density in prostate cancer patients without bone metastases treated with intermittent androgen therapy. Oncology, 17(4, Suppl.), 32-33.
Hillner, B.E., Ingle, J.N., Chlebowski, R.T., Gralow, J., Yee, G.C., Janjan, N.A., et al. (2003). American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. Journal of Clinical Oncology, 21, 4042-4057.
Hofbauer, L.C., & Khosla, S. (1999). Androgen effects on bone metabolism: Recent progress and controversies. European Journal of Endocrinology, 140, 271-286.
Jonat, W., Kaufmann, M., Sauerbrei, W., Blamey, R., Cuzick, J., Namer, M., et al. (2002). Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association study. Journal of Clinical Oncology, 20, 4628-4635.
Jordan, V.C., Gapstur, S., & Morrow, M. (2001). Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute, 93, 1449-1457.
Kanis, J.A. (2002). Diagnosis of osteoporosis and assessment of fracture risk. Lancet, 359, 1929-1936.
Kaufman, J.M., Johnell, O., Abadie, E., Adami, S., Audran, M., Avouac, B., et al. (2000). Background for studies on the treatment of male osteoporosis: State of the art. Annals of the Rheumatic Diseases, 59, 765-772.
Kiralti, B.J., Srinivas, S., Perkash, I., & Terris, M.K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. Urology, 57, 127-132.
Leder, B.Z., LeBlanc, K.M., Schoenfeld, D.A., Eastell, R., & Finkelstein, J.S. (2003). Differential effects of androgens and estrogens on bone turnover in normal men. Journal of Clinical Endocrinology and Metabolism, 88, 204-210.
Lips, P., Wilco, C., Graafmans, W.C., Ooms, M.E., Bezemer, D., & Bouter, L.M. (1996). Vitamin D supplementation and fracture incidence in elderly persons. A randomized, placebo-controlled clinical trial. Annals of Internal Medicine, 124, 400-406.
Love, R.R., Mazess, R.B., Barden, H.S., Epstein, S., Newcomb, P.A., Jordan, V.C., et al. (1992). Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. New England Journal of Medicine, 326, 852-856.
Maillefert, J.F., Sibilia, J., Michel, F., Saussine, C., Javier, R.M., & Tavernier, C. (1999). Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. Journal of Urology, 161, 1219-1222.
Melton, L.J., III, Alothman, K.I., Khosla, S., Achenbach, S.J., Oberg, A.L., & Zincke, H. (2003). Fracture risk following bilateral orchiectomy. Journal of Urology, 169, 1747-1750.
Messinger-Rapport, B.J., & Thacker, H.L. (2002). Prevention for the older woman: A practical guide to prevention and treatment of osteoporosis. Geriatrics, 57(4), 16-18, 21-24, 27.
Miller, P., & Lane, N.E. (2001). Osteoporosis: Clinical and laboratory features. In J.H. Klippel, L.J. Crofford, J.H. Stone, & C.M. Weyand (Eds.), Primer on the rheumatic diseases (12th ed., pp. 518-523). Atlanta, GA: Arthritis Foundation.
Mincey, B.A., Moraghan, T.J., & Perez, E.A. (2000). Prevention and treatment of osteoporosis in women with breast cancer. Mayo Clinic Proceedings, 75, 821-829.
Mittan, D., Lee, S., Miller, E., Perez, R.C., Basler, J.W., & Bruder, J.M. (2002). Bone loss following hypogonadism in men with prostate cancer treated with gonadotropin-releasing hormone analogs. Journal of Clinical Endocrinology and Metabolism, 87, 3656-3661.
Morabito, N., Gaudio, A., Lasco, A., Vergara, C., Tallarida, F., Crisafulli, G., et al. (2003). Three-year effectiveness of intravenous pamidronate versus pamidronate plus slow-release sodium fluoride for postmenopausal osteoporosis. Osteoporosis International, 14, 500-506.
National Osteoporosis Foundation. (2003). Physician's guide to prevention and treatment of osteoporosis. Washington, DC: Author.
National Osteoporosis Foundation. (2004a). America's bone health: The state of osteoporosis and low bone mass. Retrieved January 22, 2004, from http://www.nof.org/advocacy/prevalence/index.htm
National Osteoporosis Foundation. (2004b). Osteoporosis: Men. Retrieved January 14, 2004, from http://www.nof.org/men/index.htm
Novartis Pharmaceuticals. (2003). Aredia® [Package insert]. East Hanover, NJ: Author.
Novartis Pharmaceuticals. (2004). Zometa® [Package insert]. East Hanover, NJ: Author.
O'Connell, M.B. (1999). Osteoporosis and osteomalacia. In J.T. DiPiro, R.L. Talbert, G.C. Yee, G.R. Matzke, B.G. Wells, & L.M. Posey (Eds.), Pharmacotherapy: A pathophysiological approach (4th ed., pp. 1406-1426). Stamford, CT: Appleton and Lange.
Oefelein, M.G., Ricchuiti, V., Conrad, W., Seftel, A., Bodner, D., Goldman, H., et al. (2001). Skeletal fracture associated with androgen suppression induced osteoporosis: The clinical incidence and risk factors for patients with prostate cancer. Journal of Urology, 166, 1724-1728.
Oursler, M.J., Landers, J.P., Riggs, B.L., & Spelsberg, T.C. (1993). Oestrogen effects on osteoblasts and osteoclasts. Annals of Medicine, 25, 361-371.
Peacock, M., Liu, G., Carey, M., McClintock, R., Ambrosius, W., Hui, S., et al. (2000). Effect of calcium or 25OH vitamin D3 dietary supplementation on bone loss at the hip in men and women over the age of 60. Journal of Clinical Endocrinology and Metabolism, 85, 3011-3019.
Pfeilschifter, J., & Diel, I.J. (2000). Osteoporosis due to cancer treatment: Pathogenesis and management. Journal of Clinical Oncology, 18, 1570-1593.
Powles, T.J., Hickish, T., Kanis, J.A., Tidy, A., & Ashley, S. (1996). Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. Journal of Clinical Oncology, 14, 78-84.
Procter & Gamble Pharmaceuticals. (2003). Didronel® [Package insert]. North Norwich, NY: Author.
Ramaswamy, B., & Shapiro, C.L. (2003). Osteopenia and osteoporosis in women with breast cancer. Seminars in Oncology, 6, 763-775.
Recker, R.R., Hinders, S., Davies, K.M., Heaney, R.P., Stegman, M.R., Lappe, J.M., et al. (1996). Correcting calcium nutritional deficiency prevents spine fractures in elderly women. Journal of Bone and Mineral Research, 11, 1961-1966.
Reid, I.R., Ames, R.W., Evans, M.C., Gamble, G.D., & Sharpe, S.J. (1995). Long-term effects of calcium supplementation on bone loss and fractures in postmenopausal women: A randomized controlled trial. American Journal of Medicine, 98, 331-335.
Reid, I.R., Brown, J.P., Burckhardt, P., Horowitz, Z., Richardson, P., Trechsel, U., et al. (2002). Intravenous zoledronic acid in postmenopausal women with low bone mineral density. New England Journal of Medicine, 346, 653-661.
Saarto, R., Blomqvist, C., Valimake, M., Makela, P., Sarna, S., & Elomaa, I. (1997). Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: A randomized study in premenopausal breast cancer patients. Journal of Clinical Oncology, 15, 1341-1347.
Segal, R.J., Reid, R.D., Courneya, K.S., Malone, S.C., Parliament, M.B., Scott, C.G., et al. (2003). Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 21, 1653-1659.
Shapiro, C.L., Manola, J., & Leboff, M. (2001). Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer. Journal of Clinical Oncology, 19, 3306-3311.
Smith, M.R. (2002). Osteoporosis during androgen deprivation therapy for prostate cancer. Urology, 60(Suppl. 3A), 79-86.
Smith, M.R. (2003a). Bisphosphonates to prevent osteoporosis in men receiving androgen deprivation therapy for prostate cancer. Drugs and Aging, 20, 175-183.
Smith, M.R. (2003b). Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma. Cancer, 97(3, Suppl.), 789-795.
Smith, M.R., Eastham, J., Gleason, D.M., Shasha, D., Tchekmedyian, S., & Zinner, N. (2003). Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for non-metastatic prostate cancer. Journal of Urology, 169, 2008-2012.
Smith, M.R., McGovern, F.J., Zietman, A.L., Fallon, M.A., Hayden, D.L., Schoenfeld, D.A., et al. (2001). Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. New England Journal of Medicine, 345, 948-955.
Taxel, P., Fall, P.M., Albertsen, P.C., Dowsett, R.D., Trahiotis, M., Zimmerman, J., et al. (2002). The effect of micronized estradiol on bone turnover and calciotropic hormones in older men receiving hormonal suppression therapy for prostate cancer. Journal of Clinical Endocrinology and Metabolism, 87, 4907-4913.
Thiebaud, D., Burckhardt, P., Melchior, J., Eckert, P., Jacquet, A.F., Schnyder, P., et al. (1994). Two years' effectiveness of intravenous pamidronate (APD) versus oral fluoride for osteoporosis occurring in the postmenopause. Osteoporosis International, 4, 76-83.
Townsend, M.F., Sanders, W.H., Northway, R.O., & Graham, S.D., Jr. (1997). Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma. Cancer, 79, 545-550.
Twiss, J.J., Waltman, N., Ott, C.D., Gross, G.J., Lindsey, A.M., & Moore, T.E. (2001). Bone mineral density in postmenopausal breast cancer survivors. Journal of the American Academy of Nurse Practitioners, 13, 276-284.
USP DI® Editorial Group. (Ed). (2004). USP DI® drug information for the health care professional [Electronic version] (24th ed.). Taunton, MA:Micromedex,Inc.RetrievedJuly20,2004,fromhttp://online.statref.com/document.aspx?DocID=1&StartDoc=1&EndDoc=4569&…;
Vehmanen, L., Saarto, T., Elomaa, P., Makela, P., Valimaki, M., & Blomquist, C. (2001). Long-term impact of chemotherapy-induced ovarian failure on bone mineral density (BMD) in premenopausal breast cancer patients. The effect of adjuvant clodronate treatment. European Journal of Cancer, 37, 2373-2378.
Viale, P.H., & Sanchez Yamamoto, D. (2003). Bisphosphonates: Expanded roles in the treatment of patients with cancer. Clinical Journal of Oncology Nursing, 7, 393-401.
Vieth, R. (2001). Vitamin D nutrition and its potential health benefits for bone, cancer and other conditions. Journal of Nutritional and Environmental Medicine, 11, 275-291.
Vincent, K.R., & Braith, R.W. (2002). Resistance exercise and bone turnover in elderly men and women. Medicine and Science in Sports and Exercise, 34, 17-23.
Ward, R.L., Morgan, G., Dalley, D., & Kelly, P.J. (1993). Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone and Mineral, 22, 87-94.
WPS Medicare Administrators. (2004). Wisconsin medical policy index: Bisphosphonate drug therapy. Retrieved July 20, 2004, from http://www.wpsic.com/medicare/policies/wisconsin/inj25.shtml